Can MIS (minimally invasive surgery) really reduce costs in the UK?
This article was originally published in Clinica
The UK government hopes that an increased use of minimally invasive surgery (MIS) will result in economies to the health services and free up resources and hospital space for other patients. This is one of the key criteria in its plans to reduce waiting lists. But is the basis of its assumptions that MIS reduces costs correct? Or are the cost-savings of MIS dependent of a significant reorganisation in National Health Service treatment facilities? These were the questions tackled at the Health Service Journal's meeting on June 15 in London.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.